Eisai, Arena ask FDA to bless extended-release Belviq; J&J files for Stelara nod in Crohn's;

@FiercePharma: Japan reaping the benefits from faster approval process. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: last week: FDA warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce: last week: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Eisai and Arena Pharmaceuticals ($ARNA) said the FDA accepted their application for approval of an extended-release version of their anti-obesity med Belviq. Release

> Johnson & Johnson ($JNJ) asked the FDA to approve expanded use of its anti-inflammatory drug Stelara, for patients with Crohn's Disease; the drug is already used to treat psoriasis and psoriatic arthritis. Release

> One analyst's survey found that 90% of industry respondents think Pfizer ($PFE) will hive off its established products unit after its proposed $160 billion megamerger with Allergan ($ACT). Report

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article | Follow @FierceMedDev

@VarunSaxena2: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: A behind-the-scenes look at Cards Against Biotechnology, Cubist's snarky 'last hurrah': FiercePharmaMarketing item | Follow @EmilyWFierce

> Nevro scores a victory in spinal cord stimulation patent battle with Boston Scientific. Article

> Q&A: Philips on what's next after the first year of HealthTech. Report

Biotech News

@FierceBiotech: Real R&D innovation demands that lines between academia and industry are blurred. Article | Follow @FierceBiotech

@JohnCFierce: Disgraced scientist's China venture resurrects fears of a human cloning comeback. Story | Follow @JohnCFierce

@DamianFierce: Actually, inversions are ... good? More from the NYT | Follow @DamianFierce

> Foundering Xoma flips its diabetes program to Novo Nordisk in a $295M deal. Report

> For real R&D innovation, blur the lines between pharma and academia: Panel. Editor's corner

> FDA to Repros: Wipe your PhIII drawing board clean and start over. More

> Puma preps its once-vaunted cancer drug for European submission. Article

Pharma Manufacturing News

> Xellia buys idled Bedford plant from Hikma, will hire 170. Report

> FDA warning letter blasts Dr. Reddy's for undisclosed testing. News

> Samsung BioLogics to build its third and largest plant in South Korea. Story

> Meda sells off Spain operation that makes Legalon API. Article

> GE investing $40M in Ireland plant and will add 140 jobs. Item

Pharma Asia News

> Pharmaceuticals in South Korea could drive economy's growth. Item

> Survey: Rates of HIV in Asia could reflect 'hidden epidemic.' More

> Israel's Teva and Takeda tie up for Japan generics business. Report

> Delhi court rules for Dr. Reddy's in Xarelto case. Story

> Russia hopes to lure drugmakers with increase in buying power. Article

Drug Delivery News

> Nature: Electronic on-demand delivery device is also bioresorbable. More

> Indian Institute of Science develops hep C delivery vehicle using siRNA. Story

> UCSD develops tech to isolate drug-delivery nanoparticles from the blood. Item

> Presage licenses cancer drug from India's Piramal to accelerate development using its microinjector. Report

> Impax earns permission to sell its FDA-approved modified-release Parkinson's med in Europe. Article

And Finally... Light therapy, often used to treat seasonal depression, may work for the non-seasonal kind, a study found. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.